NJ-LABVANTAGE
22.2.2024 13:31:32 CET | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, has made available its semantic search (AILANI), advanced analytics, and LIMS solutions in an integrated, digitally native ecosystem capable of seamlessly supporting R&D laboratory processes. This ecosystem will enable R&D labs to improve efficiency, productivity, decision-making, collaboration, and ultimately time-to-market while reducing operational cost. LabVantage will present its LIMS solutions and integrated ecosystem at Pittcon 2024 (Booth #2133), February 24-28, in San Diego, California.
Digitizing R&D laboratory processes with advanced technologies such as semantic search, analytics, and LIMS marks a significant leap towards efficiency and innovation in the scientific domain. Semantic search capabilities enable the contextualization and searchability of vast amounts of data and documents, utilizing a semantic core and knowledge graph. This technology not only streamlines information retrieval and drastically reduces repetition in experimental runs, but also enhances the decision-making process by providing more relevant and precise data insights. Some LabVantage customers have experienced a 30% reduction in repeated experiments by implementing LabVantage’s semantic search tool, AILANI.
Integrating AI and Business Intelligence into a unified analytics platform, in tandem with LIMS, accelerates analysis and reporting. LabVantage Analytics provides analysis of both structured and unstructured data from diverse sources, integrating data processing, storage, analysis, and visualization in one platform. Its user-friendly self-service features include customizable dashboards and immediate access to LIMS data reports.
“By incorporating advanced technologies like semantic search, AI, and analytics into our LIMS solutions, we're not only enhancing data precision and reducing experimental repetition but also driving significant improvements in collaboration and experiment design. Together, these tools will be instrumental in enabling customers to design better experiments while drastically reducing the total number of experimental runs,” said Alan Marcus, Chief Growth Officer at LabVantage Solutions. “Our goal is to hand back more time to customers for scientific exploration. In fact, we believe these digitally native solutions will expand our ability to serve clients in all supported industries throughout their entire product lifecycle. Your data can now be unified, housed, searched, and analyzed within a single platform from concept to market.”
The implementation of a LIMS automates and manages laboratory workflows, significantly boosting efficiency and consistency in experiment execution. By integrating with search and analytics tools, LabVantage LIMS ensures a seamless flow of information, further elevating laboratory operations, decision-making, and collaboration. Industry statistics underscore the transformative impact of such digitization and automation with laboratories reporting up to a 30-40% increase in productivity.1
LabVantage’s merger with Biomax Informatics has enhanced its analytics and LIMS solutions by integrating AILANI, an advanced semantic search tool. AILANI synergizes semantic modeling, ontologies, linguistics, and AI algorithms to revolutionize query-based research. This tool effectively connects various data sources—internal, external, and proprietary—empowering researchers to swiftly discover valuable insights and hidden patterns. It also simplifies and accelerates decision-making throughout the R&D process by offering easy access to relevant information and its context.
LabVantage Biomax was recognized in the Gartner® Hype Cycle™ for Life Science Discovery Research 2023 as a Sample Vendor for two categories: ‘Semantic Knowledge Graph Tools’ and ‘Analytics Platforms for Research Informatics’.2 Similarly, LabVantage was ranked as a top growth and innovation leader in 2023 by Frost & Sullivan in the firm’s first annual global life sciences LIMS report and radar, highlighting LabVantage's commitment and status as a pivotal player in transforming life science research and analytics.
For more information on LabVantage, its LIMS solutions, and digitally native R&D ecosystem, visit www.labvantage.com or email info@labvantage.com.
References:
- McKinsey & Company. Digitization, Automation, and Online Testing: The Future of Pharma Quality Control. McKinsey & Company Life Sciences.
-
Harwood, R. Gartner® Hype Cycle™ for Life Science Discovery Research, 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222841525/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 09:00:00 CET | Press release
Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn
Reges Elektrik Acquires the Demirli Wind Power Plant, One of Türkiye’s Most Significant Wind Energy Projects2.2.2026 09:00:00 CET | Press release
Reges Elektrik, a dynamic and innovative leader in the Turkish energy sector, has announced the acquisition of Tuşpa Enerji Üretim A.Ş. as part of its strategic growth roadmap. Through this landmark acquisition, Reges Elektrik will launch electricity production at the 70 MW Demirli Wind Power Project, located in the Kaman district of Kırşehir. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126059611/en/ From left to right: Enver Altuncu, General Manager and Board Member at Reges Elektrik; Cansu Ünal Öngören, CFO and Board Member at Reges Elektrik; Geert Dooms, General Manager at RES Türkiye; Kağan Gilik, Deputy General Manager at RES Türkiye. Acquired from RES Türkiye, a subsidiary of RES Group—the world’s largest independent renewable energy company—the Demirli Project represents a pivotal milestone in Reges Elektrik’s decisive expansion into energy production. With this investment, the company scales its operations to i
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 08:00:00 CET | Press release
Delivery of the Black Hornet UAV systems to Swiss Armed Forces will include drones with software and integration kit specially designed to work with Piranha 8x8 vehicle digital infrastructureWork shows promise and market potential for UAS armored vehicle integrations to enhance tactical operations Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom